POSTER: AML-732 Ziftomenib Combined With Intensive Induction Chemotherapy (7+3) in Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia (AML): Updated Phase 1a/b Results From KOMET-007
Amer M. Zeidan(Yale Cancer Center), Harry P. Erba(Michigan Center for Translational Pathology), Amir T. Fathi(University of Southern California), Mohamad Khawandanah(University of Oklahoma Health Sciences Center), Gail J. Roboz(Cornell University), Jörge E. Cortes(Augusta University Health), Julie Mackey Ahsan(Kura Oncology (United States)), James K. Mangan(UC San Diego Health System), Jessica K. Altman(Northwestern University), Michael Schuster(Austrian Academy of Sciences), Stephen A. Strickland(Vanderbilt University), Tara L. Lin(Dana-Farber Cancer Institute), Daniel Corum(Fujikura (United States)), Gary J. Schiller(Fred Hutch Cancer Center), Eunice S. Wang(Roswell Park Comprehensive Cancer Center), Keith W. Pratz(University of Pennsylvania), Ivana Gojo(Johns Hopkins University), Neil Palmisiano(Thomas Jefferson University Hospital), Marina Kremyanskaya(Tisch Cancer Institute), Talha Badar(Mayo Clinic in Florida), Leonard C. Alsfeld(Ochsner Medical Center), James S. Blachly(The Ohio State University Wexner Medical Center), Anjali S. Advani(Cleveland Clinic), Suresh Kumar Balasubramanian(Cleveland Clinic), Kiran Naqvi(The University of Texas MD Anderson Cancer Center), Tianle Chen(Biogen (United States)), Yazan F. Madanat(The University of Texas Southwestern Medical Center), Mollie Leoni(Kura Oncology (United States)), Kalyan Nadiminti(University of Wisconsin Carbone Cancer Center), Mark Juckett(UW Health University Hospital), Marcello Rotta(Colorado Blood Cancer Institute), Marcie Riches(Medical College of Wisconsin)
Cited by 0
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease
|The Journal of Prevention of Alzheimer s Disease|2022|1.3k